课题基金 / 基金详情

Development & evaluation of liposomal TLR7 agonist combined with immunotherapeutic antibodies for treating pancreatic cancer

Development & evaluation of liposomal TLR7 agonist combined with immunotherapeutic antibodies for treating pancreatic cancer
发展
批准号：
412388
负责人：
Tang Wei-Lun
金额：
$7.29万
依托单位：
Stanford University (California)
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2019
资助国家：
加拿大
项目状态：
已结题
起止时间：
2019-10-01 至 2021-10-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=412388&lang=en
关键词：
Biomedical Imaging Cancer Immunotherapy Pancreatic Cancer Small Drug Delivery Targeted Therapy Therapeutic Antibodies

项目摘要

项目成果

Tang Wei-Lun的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Pancreatic ductal adenocarcinoma (PDAC), which constitutes 90% of pancreatic cancers, is the fourth leading cause of cancer-related deaths in the world with high mortality (< 8% survival rate beyond 5 years following diagnosis) due to poor prognosis and l
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Development of the liposomal formulation of 6-Mercaptopurine (6-MP) for improved oral absorption and enhanced therapeutic outcome against cancer
  • 批准号：
    375846
  • 项目类别：
    Miscellaneous Programs
  • 资助金额：
    $0.44万
  • 财政年份：
    2017
  • 负责人：
    Tang Wei-Lun
  • 依托单位：
    University of Tokushima (Japan)
海外基金